Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04667572 · ClinicalTrials.gov registry record · Phase 1
Safety & Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution
A Phase 1 study of Keratoconus and Pellucid Marginal Corneal Degeneration, sponsored by Cornea Associates of Texas.
- Completed
- Registry status
- Phase 1
- Development phase
- 249
- Enrollment target
- 1
- Study location
NCT04667572: Completed Phase 1 study of Keratoconus and Pellucid Marginal Corneal Degeneration, sponsored by Cornea Associates of Texas.
NCT04667572 is a Phase 1 study of Keratoconus and Pellucid Marginal Corneal Degeneration that has completed, run by Cornea Associates of Texas. The registered enrollment target is 249 participants, below the 1,169-participant average among 21 other Keratoconus trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04667572, a Phase 1 study of Keratoconus and Pellucid Marginal Corneal Degeneration, has completed, sponsored by Cornea Associates of Texas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 249 participants
- Enrollment target
- 1
- Study location
Study Summary
Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Collagen Cross-linking in Eyes With Corneal Thinning Conditions
Primary Outcome
Change in K-Max measured by corneal topography, compared to baseline
Conditions Studied
Interventions
- COMBINATION_PRODUCT PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Study Locations (1)
Texas
- Cornea Associates of Texas - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 249 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2024-08-21 |
| Phase | Phase 1 |
What the finished NCT04667572 record still lists
NCT04667572 is an interventional study that assigns participants to a tested intervention. The registered 249 participants enrollment target is mid-sized for trials with a published cap, below the 1,169-participant average among 21 other Keratoconus trials with a reported enrollment target (79% lower).
The record links to 4 conditions, with Keratoconus appearing as the primary indexed condition, and to 1 intervention - of which PXL-330 Platinum device for crosslinking with Peschke riboflavin solution is the first listed.
NCT04667572 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04667572 about?
NCT04667572 is a clinical study titled "Safety & Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution". Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Collagen Cross-linking in Eyes With Corneal Thinning Conditions
What is the current status of trial NCT04667572?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 249 participants. The study started on 2021-02-01. Estimated completion is 2024-08-21.
What conditions does trial NCT04667572 study?
This clinical trial studies the following conditions: Keratoconus, Pellucid Marginal Corneal Degeneration, Corneal Ectasia, Corneal Degeneration.
What interventions are being tested in trial NCT04667572?
The interventions under investigation include: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04667572?
This trial is sponsored by Cornea Associates of Texas, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04667572 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Keratoconus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04667572's enrollment target sits among peer trials
249 10th of 21 higher than 12 of 21 other Keratoconus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Keratoconus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
RECRUITING
-
OCT in Diagnosis of Irregular Corneas
RECRUITING
-
Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
RECRUITING · Phase 3
-
Collagen Cross-linking in Keratoconus
RECRUITING · NA
-
Corneal Elastography and Patient Specific Modeling
RECRUITING
-
Compassionate Use Study of Epi-ON Corneal Collagen Crosslinking Performed Using UVA Exposure on Eyes With Ectatic Corneal Diseases for Subjects With Down Syndrome
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04628767 · 249 participants · Phase 2
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
- NCT05834907 · 249 participants · NA
Hands and Hearts Together
- NCT06067555 · 249 participants · Early Phase 1
Intradermal Influenza Vaccination
- NCT06588478 · 249 participants · Phase 2
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI